The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Knights plunges after profit warning

Tue, 22nd Mar 2022 11:50

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Pebble Group PLC, up 17% at 105.60 pence, 12-month range 85.00p-169.87p. The technology and services promotional products supplier delivers strong performance in 2021, expecting further significant growth opportunities ahead. For 2021, Pebble posts pretax profit GBP9.3 million, up from GBP5.0 million in 2020 on revenue of GBP115.1 million, up from GBP82.4 million. Says 2022 has started well and in line with expectations and looks forward to the year ahead and beyond with confidence.

----------

AIM - LOSERS

----------

Knights Group Holdings PLC, down 48% at 191.44p, 12-month range 188.00p-472.00p. The legal and professional services provider warns Omicron variant and recent macro conditions have slowed growth to a greater extent than anticipated. For year ending April 30, expects adjusted pretax profit - which strips out exceptional and other one-off items - to be GBP18 million. Revenue is forecast to be around GBP126 million. "We have also seen a softening in business confidence, possibly due to concerns around the strength of the economy, such that there has been a slowdown in corporate work," company says.

----------

Diurnal Group PLC, down 41% at 19.63p, 12-month range 17.20p-97.97p. The pharmaceutical company warns further financing will be required if it is to reach sustainable profitability. For six months to December 31, pretax loss widens to GBP9.2 million from loss of GBP5.2 million year before on revenue of GBP2.1 million from GBP1.2 million. Says further financing will be required prior to reaching sustainable profitability. "This requirement for additional financing represents a material uncertainty that may cast significant doubt upon the group's and parent company's ability to continue as a going concern," it says.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 May 2020 13:07

UK EXECUTIVE CHANGE SUMMARY: Abcam Board Confirms Support For Chair

UK EXECUTIVE CHANGE SUMMARY: Abcam Board Confirms Support For Chair

Read more
15 Apr 2020 14:32

UK TRADING UPDATE SUMMARY: Kromek To Make 2,000 Ventilators For UK

UK TRADING UPDATE SUMMARY: Kromek To Make 2,000 Ventilators For UK

Read more
1 Apr 2020 14:47

Diurnal Gets European Marketing Authorisation For Chronocort

Diurnal Gets European Marketing Authorisation For Chronocort

Read more
6 Mar 2020 17:12

UPDATE: Diurnal Placing Raises GBP11 Million For Drug Development

UPDATE: Diurnal Placing Raises GBP11 Million For Drug Development

Read more
6 Mar 2020 12:40

Diurnal Announces GBP7 Million Placing To Fund Drug Development

Diurnal Announces GBP7 Million Placing To Fund Drug Development

Read more
6 Mar 2020 10:07

Diurnal raises at least ?7m through conditional placing

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced a conditional placing with institutional investors on Friday, to raise at least ?7m before expenses, at a price of 32p per new share.

Read more
5 Mar 2020 17:21

Diurnal Group Names Director Sam Williams Interim Chair

Diurnal Group Names Director Sam Williams Interim Chair

Read more
13 Feb 2020 13:07

Diurnal Says US FDA Accepts New Drug Application For Alkindi Sprinkle

Diurnal Says US FDA Accepts New Drug Application For Alkindi Sprinkle

Read more
13 Feb 2020 09:47

Diurnal clears FDA hurdle for 'Alkindi Sprinkle'

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Thursday that its new drug application (NDA) for 'Alkindi', or hydrocortisone granules in capsules for opening and to be known in the US as 'Alkindi Sprinkle', has been accepted for review by the US Food and Drug Administration (FDA).

Read more
11 Feb 2020 13:45

Diurnal narrows loss as it progresses drugs to market

(Sharecast News) - Speciality pharmaceutical company Diurnal Group narrowed its first-half loss by 53% to ?4.6m, it announced on Tuesday, which it said reflected improved revenues and a reduction in clinical development expenses for the period.

Read more
11 Feb 2020 09:20

Diurnal Loss Narrows In First Half Amid Improved Sales Of Alkindi

Diurnal Loss Narrows In First Half Amid Improved Sales Of Alkindi

Read more
4 Feb 2020 15:54

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
20 Jan 2020 11:17

Diurnal In Good Health Ahead Of Second Half Amid Alkindi Progress

Diurnal In Good Health Ahead Of Second Half Amid Alkindi Progress

Read more
16 Dec 2019 13:20

Diurnal Submits Market Authorisation Application For Chronocort

Diurnal Submits Market Authorisation Application For Chronocort

Read more
2 Dec 2019 14:40

Diurnal Submits New Drug Application For Aklindi Sprinkle In US

Diurnal Submits New Drug Application For Aklindi Sprinkle In US

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.